Abstract:Structural classification and regulatory functions of histone deacetylases and their inhibitors. Epigenetic regulation of genes through posttranslational regulation of proteins is a well‐explored approach for disease treatment, particularly in cancer chemotherapy. Histone deacetylases have shown significant potential as effective drug targets in therapeutic studies aiming to restore epigenetic normality in oncology. Besides their role in modifying histones, histone deacetylases can also catalyze the deacetylation of various nonhistone proteins and participate in the regulation of multiple biological processes. This paper provides a review of the classification, structure, and functional characteristics of the four classes of human histone deacetylases. The increasing abundance of structural information on HDACs has led to the gradual elucidation of structural differences among subgroups and subtypes. This has provided a reasonable explanation for the selectivity of certain HDAC inhibitors. Currently, the US FDA has approved a total of six HDAC inhibitors for marketing, primarily for the treatment of various hematological tumors and a few solid tumors. These inhibitors all have a common pharmacodynamic moiety consisting of three parts: CAP, ZBG, and Linker. In this paper, the structure–effect relationship of HDAC inhibitors is explored by classifying the six HDAC inhibitors into three main groups: isohydroxamic acids, benzamides, and cyclic peptides, based on the type of inhibitor ZBG. However, there are still many questions that need to be answered in this field. In this paper, the structure‐functional characteristics of HDACs and the structural information of the pharmacophore model and enzyme active region of HDAC is are considered, which can help to understand the inhibition mechanism of the compounds as well as the rational design of HDACs. This paper integrates the structural‐functional characteristics of HDACs as well as the pharmacophore model of HDAC is and the structural information of the enzymatic active region, which not only contributes to the understanding of the inhibition mechanism of the compounds, but also provides a basis for the rational design of HDAC inhibitors.

Cyclic Peptide Histone Deacetylase Inhibitors

Advances in Research on Cyclic Peptide Histone Deacetylase Inhibitors

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Synthesis, Evaluation and Molecular Modeling of Cyclic Tetrapeptide Histone Deacetylase Inhibitors As Anticancer Agents.

New Development of HDAC Inhibitors As Anti-Cancer Agents

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Synthesis, Biological Evaluation and Molecular Modeling of Cyclic Tetrapeptide Based Inhibitors Hdac

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Strategies in Developing Promising Histone Deacetylase Inhibitors.

Discussion on structure classification and regulation function of histone deacetylase and their inhibitor

Targeting histone deacetylases for cancer therapy: Trends and challenges

An Overview of HDAC Inhibitors and Their Synthetic Routes.

Advances of histone deacetylases inhibitors as novel anti-cancer agents in clinical study

Histone Deacetylase (HDAC) Inhibitors in Cancer: a Patent Review (2017-Present)

Anticancer activities of histone deacetylase inhibitors

The Structure and Function of Histone Deacetylases: the Target for Anti-cancer Therapy

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Histone Deacetylase Inhibitors as Anticancer Drugs

Hdac1/3 Dual Selective Inhibitors - New Therapeutic Agents For The Potential Treatment Of Cancer

Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker

Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy